Innovative Research Award
Youngjoo Kwon – Ewha Womans University
Youngjoo Kwon is a Professor at Ewha Womans University whose research focuses on anticancer drug discovery, molecular pharmacology, and medicinal chemistry. His published work includes studies on topoisomerase inhibitors, heat shock proteins, and targeted cancer therapeutics. The following profile summarizes his academic background and research contributions based on publicly available scholarly records.[1]
Abstract
Professor Youngjoo Kwon has contributed extensively to anticancer drug development through studies involving DNA topoisomerase inhibition, molecular signaling pathways, and therapeutic target discovery. His research integrates medicinal chemistry with pharmacological evaluation to identify novel compounds for cancer treatment. Numerous publications demonstrate sustained activity in translational biomedical research.[2]
Keywords
Anticancer drug development, medicinal chemistry, molecular pharmacology, DNA topoisomerase inhibitors, HSP27, targeted therapy, drug discovery, cancer biology.
Introduction
Youngjoo Kwon has established a research program centered on the discovery and optimization of therapeutic compounds for cancer treatment. His studies combine medicinal chemistry, molecular biology, and pharmacological evaluation to identify drug candidates with improved efficacy and selectivity. Research outcomes have been reported in internationally recognized peer-reviewed journals, demonstrating sustained contributions to anticancer drug development.[5]
Research Profile
Since joining Ewha Womans University, Youngjoo Kwon has led research in oncology-focused medicinal chemistry with emphasis on novel small-molecule therapeutics. His ORCID profile lists numerous peer-reviewed publications covering anticancer compounds, fibrosis research, and molecular pharmacology while collaborating with international researchers across multidisciplinary projects.[3]
Research Contributions
His research has contributed to the understanding of DNA topoisomerase inhibition, heat shock protein biology, tumor progression, fibrosis, and molecular mechanisms associated with therapeutic resistance. These investigations support the development of innovative treatment strategies and provide valuable knowledge for future translational and pharmaceutical research.[2]
Publications
Youngjoo Kwon has authored and co-authored research articles published in internationally recognized journals including European Journal of Medicinal Chemistry, EMBO Reports, Journal of Medicinal Chemistry, and Pharmaceuticals. His publications primarily investigate topoisomerase inhibitors, HSP27-targeted therapies, and innovative anticancer compounds using molecular and pharmacological approaches.[4]
Research Impact
The research profile reflects continuous scientific productivity through numerous peer-reviewed publications, collaborations, and contributions to medicinal chemistry. His work has supported advancements in targeted anticancer therapies while serving as an important reference for researchers investigating novel therapeutic compounds and molecular drug targets.[3]
Award Suitability
Based on publicly available scholarly information, Youngjoo Kwon demonstrates an extensive record of research activity in medicinal chemistry and anticancer drug development. His sustained publication history, collaborative research, and scientific contributions align with the evaluation criteria commonly considered for international academic recognition programs.[1]
Conclusion
Youngjoo Kwon continues to contribute to cancer pharmacology through innovative medicinal chemistry research and multidisciplinary collaborations. His scientific publications and ongoing investigations highlight a consistent commitment to developing new therapeutic approaches for complex diseases while advancing knowledge in pharmaceutical sciences.
External Links
References
- Seo, S. H., Hwang, S. Y., Hwang, S., Han, S., Park, H., Lee, Y. S., Rho, S. B., & Kwon, Y. (2022). Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R. EMBO Reports, 23.
https://doi.org/10.15252/embr.202152977
- Hwang, S. Y., Shrestha, A., Park, S., Bist, G., Kunwar, S., Kadayat, T. M., Jang, H., Seo, M., Sheen, N., Kim, S., Lee, E. S., & Kwon, Y. (2022). Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors. European Journal of Medicinal Chemistry, 227, 113916.
https://doi.org/10.1016/j.ejmech.2021.113916
- Jeon, K. H., Park, S., Jang, H. J., Hwang, S. Y., Shrestha, A., Lee, E. S., & Kwon, Y. (2021). AK-I-190, a new catalytic inhibitor of Topoisomerase II with anti-proliferative and pro-apoptotic activity on androgen-negative prostate cancer cells. International Journal of Molecular Sciences, 22(20), 11246.
https://doi.org/10.3390/ijms222011246
- Yim, J., Lim, H. H., & Kwon, Y. (2021). COVID-19 and pulmonary fibrosis: Therapeutics in clinical trials, repurposing, and potential development. Archives of Pharmacal Research, 44, 499-513.
https://doi.org/10.1007/s12272-021-01331-9
- Kadayat, T. M., Park, S., Shrestha, A., Jo, H., Hwang, S. Y., Katila, P., Shrestha, R., Nepal, M. R., Noh, K., Kim, S. K., Lee, E. S., & Kwon, Y. (2019). Discovery and biological evaluations of halogenated 2,4-diphenyl indeno[1,2-b]pyridinol derivatives as potent Topoisomerase IIα-targeted chemotherapeutic agents for breast cancer. Journal of Medicinal Chemistry, 62(19), 9195-9213.
https://doi.org/10.1021/acs.jmedchem.9b00970